ASH 2025: Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma An estimated 1 in 8 people with chronic lymphocytic leukemia (CLL) or small cell leukemia (SLL) develop another type of cancer at some point during their lifetime. This…
ASH 2025: Phase II Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma: 15-year Follow-Up Data from MDACC Trial Several studies have demonstrated the efficacy of lenalidomide plus rituximab, known as R2, in follicular lymphoma (FL). The long-term…
The 16 Career Development Award and Postdoctoral Fellowship research grants include projects exploring numerous disease subtypes treatments, including rare disease states like T-cell lymphomas, as well as novel therapeutics.
The 16 Career Development Award and Postdoctoral Fellowship research grants include projects exploring numerous disease subtypes treatments, including rare disease states like T-cell lymphomas, as well as novel therapeutics.
Lymphoma Research Foundation Awards 24 Grants to Next Generation of Lymphoma Scientists to Advance Critical Research Foundation Underscores Commitment to Lymphoma Research with Multi-Million Dollar Investment The Lymphoma Research Foundation, the nation’s largest nonprofit organization devoted to funding innovative lymphoma…
Updates from the 2024 American Society of Hematology Annual Meeting The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 264 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific…
ASH 2024: Inequitable Patterns in Fertility Counseling Reported by Patients with NHL Late effects from non-Hodgkin lymphoma (NHL) treatment can lead to decreased fertility, which may be of particular concern for adolescents and young adults. Utilization of fertility counseling is…
ASH 2024: Real-World Clinical Outcomes With Novel Therapies in Relapsed/Refractory MCL Vary Based on Race and Ethnicity The treatment for relapsed/refractory mantle cell lymphoma (MCL) has been revolutionized by the emergence of novel therapies such as Bruton’s tyrosine kinase inhibitors…
ASH 2024: First-Line Treatment Choice Impacts Risk for Other Malignancies in CLL and SLL Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have previously been shown to be at increased risk for developing other malignancies relatively to…
ASH 2024: Interim Results from the AMPLIFY Study Show Durable Responses with Acalabrutinib Plus Venetoclax in Treatment-Naïve CLL Use of fixed-duration Bruton tyrosine kinase inhibitor (BTKi) therapy in treatment-naïve chronic lymphocytic leukemia (CLL) is complicated by the limited efficacy and…
